CPT1A and B-cell chronic lymphocytic leukemia: Additionally, the novel CPT1A inhibitor ST1326 demonstrated potent anticancer activity in preclinical models, inhibiting FAO, inducing apoptosis, and causing mitochondrial damage in patient-derived leukaemia cells (AML, ALL, CLL) [98] (Table 1).